Literature DB >> 14745711

Influence of human leukocyte antigen class II alleles on susceptibility to Entamoeba histolytica infection in Bangladeshi children.

Priya Duggal1, Rashidul Haque, Shantanu Roy, Dinesh Mondal, R Bradley Sack, Barry M Farr, Terri H Beaty, William A Petri.   

Abstract

BACKGROUND: The association of antibody responses with both innate and acquired immunity to amebiasis indicate that CD4+ T cells play a role in protection against Entamoeba histolytica infection. To test this hypothesis, we compared the genotype frequencies of human leukocyte antigen (HLA) class II alleles in a cohort of Bangladeshi children intensively monitored for E. histolytica infection for a 3-year period.
METHODS: Using logistic regression, we calculated the odds of disease by genotype and by haplotype.
RESULTS: The DQB1*0601 heterozygous and homozygous genotypes were found in 55% of E. histolytica-negative children but in only 34% of E. histolytica-positive children (overall odds ratio, 2.39; 95% confidence interval [CI], 1.26-4.54). Children who were heterozygous for the DQB1*0601/DRB1*1501 haplotype were 10.1 times (95% CI, 2.02-50.6) more likely to be both E. histolytica negative and serum anti-lectin immunoglobulin G negative at baseline. Other DQB1 and DRB1 alleles (DQB1*0202, DQB1*0301, and DRB1*0701) were not associated with any of the clinical outcomes related to amebiasis.
CONCLUSION: A potential protective association was observed with the HLA class II allele DQB1*0601 and the heterozygous haplotype DQB1*0601/DRB1*1501. This association may explain why amebiasis does not occur in some children who are exposed to the parasite and implicates HLA class II-restricted immune responses in protection against E. histolytica infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14745711     DOI: 10.1086/381272

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  32 in total

Review 1.  Current therapeutics, their problems, and sulfur-containing-amino-acid metabolism as a novel target against infections by "amitochondriate" protozoan parasites.

Authors:  Vahab Ali; Tomoyoshi Nozaki
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

2.  Genes influencing susceptibility to infection.

Authors:  William A Petri; Beth D Kirkpatrick; Rashidul Haque; Priya Duggal
Journal:  J Infect Dis       Date:  2008-01-01       Impact factor: 5.226

Review 3.  Genetics of susceptibility to infection with enteric pathogens.

Authors:  Jose Flores; Pablo C Okhuysen
Journal:  Curr Opin Infect Dis       Date:  2009-10       Impact factor: 4.915

Review 4.  Enteric infections, diarrhea, and their impact on function and development.

Authors:  William A Petri; Mark Miller; Henry J Binder; Myron M Levine; Rebecca Dillingham; Richard L Guerrant
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

Review 5.  Tissue destruction and invasion by Entamoeba histolytica.

Authors:  Katherine S Ralston; William A Petri
Journal:  Trends Parasitol       Date:  2011-03-26

6.  The E. histolytica Genome Structure and Virulence.

Authors:  Carol A Gilchrist
Journal:  Curr Trop Med Rep       Date:  2016-10-03

7.  Comparative genomic hybridizations of Entamoeba strains reveal unique genetic fingerprints that correlate with virulence.

Authors:  Preetam H Shah; Ryan C MacFarlane; Dhruva Bhattacharya; John C Matese; Janos Demeter; Suzanne E Stroup; Upinder Singh
Journal:  Eukaryot Cell       Date:  2005-03

Review 8.  Burden of disease from cryptosporidiosis.

Authors:  Debbie-Ann T Shirley; Shannon N Moonah; Karen L Kotloff
Journal:  Curr Opin Infect Dis       Date:  2012-10       Impact factor: 4.915

Review 9.  Using differential gene expression to study Entamoeba histolytica pathogenesis.

Authors:  Carol A Gilchrist; William A Petri
Journal:  Trends Parasitol       Date:  2009-02-13

10.  Does genetic diversity predict health in humans?

Authors:  Hanne C Lie; Leigh W Simmons; Gillian Rhodes
Journal:  PLoS One       Date:  2009-07-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.